Open Nav


Tuesday, October 16, 2018 | 1:00pm - 6:30pm

The BIO SPARK Showcase aims to provide an excellent opportunity for academic researchers in the SPARK network to showcase drug development programs that are ready for partnering or venture funding.

The BIO Investor Forum is historically well attended by the venture arms and business development units of major pharmaceutical companies, smaller specialty pharma/biotech companies looking to add to their pipelines, start-ups, and many early stage venture capital firms, making it the ideal setting for early stage assets from the university setting. Academics interested in partnering will present their programs and also have one-on-one discussions with interested parties. 

2018 BIO SPARK Showcase Presentation Schedule


Spark Affiliate and Program

1:00 PM - 1:10 PM
Welcome from SPARK Translational Research Program, Stanford Medicine
  • Kevin Grimes, MD, Co-Director
1:10 PM - 1:30 PM
Stanford University—Bert Pharma
New Small Molecule Anesthetics for high risk infants/ elderly
Ed Bertaccini
1:30 PM - 1:50 PM
SPARK Colorado- Aurora Oncology
Intravesical DAB389EGF for the treatment of bladder cancer
Professor Michael Glode
1:50 PM - 2:10 PM
Stanford University
Novel Treatment for Kidney Cancer
Arvin Gouw/ Dean Felsher
2:10 PM - 2:30 PM
SPARK Colorado- ThromboTherapeutics Inc
tPA-Challenged™ Viscoelastometric Hemostatic Assay for Early Identification of Life-Threatening Coagulopathy in Trauma
Michael Chapman, Resident at Department of Radiology


2:30 PM - 2:40 PM
2:40 PM - 3:00 PM
Stanford University
Transient Telomere extension for liver failure
John Ramunas
3:00 PM - 3:20 PM
SPARK Finland- SCellOmics
Novel single cell omics methods
Saavalainen, Päivi
3:20 PM - 3:40 PM
Stanford University- Hyalos Therapeutics
Stopping Autoimmune Disease by Oral Induction of Treg
Marc Unger
3:40 PM - 4:00 PM
SPARK Finland- Sartar Therapeutics
Targeted GIST therapy
Harri Sihto
4:00 PM - 4:10 PM
4:10 PM - 4:30 PM
Stanford University
Platform technology for gene delivery
Ole Audun Werner Haabeth
4:30 PM - 4:50 PM
SPARK Taiwan
Development of the drug to treat opioid addiction
Amy Lai
4:50 PM - 5:10 PM
SPARK Australia- Monash University
Curative approach to inflammatory and autoimmune diseases
Professor Charles Mackay
5:10 PM - 5:30 PM
Stanford University- Facile Therapeutics
Development of a de-risked, phase 2-ready treatment for C. difficile infections
Marc Navre
5:30 PM - 6:30 PM